Bvf Partners L. P/Il Acquires 317,167 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bvf Partners L. P/Il acquired 317,167 shares of the firm's stock in a transaction dated Monday, June 30th. The stock was bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares of the company's stock, valued at approximately $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kymera Therapeutics Trading Up 0.6%

Shares of KYMR stock traded up $0.28 on Friday, reaching $44.81. 240,486 shares of the company's stock were exchanged, compared to its average volume of 632,626. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The stock has a market capitalization of $2.92 billion, a PE ratio of -14.45 and a beta of 2.18. The company's fifty day simple moving average is $38.46 and its 200 day simple moving average is $35.92.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The business's revenue was up 114.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.69) earnings per share. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KYMR has been the topic of a number of recent analyst reports. Morgan Stanley began coverage on Kymera Therapeutics in a report on Thursday. They set an "overweight" rating and a $70.00 price target on the stock. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a report on Monday, June 2nd. UBS Group decreased their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, B. Riley upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $38.00 to $60.00 in a research report on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $59.11.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming purchased a new stake in Kymera Therapeutics in the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV boosted its holdings in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after purchasing an additional 328 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the first quarter worth approximately $68,000. Finally, Advisors Asset Management Inc. increased its holdings in Kymera Therapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company's stock worth $136,000 after purchasing an additional 2,230 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.